Jay Gregory D, Fleming Braden C, Watkins Bryn A, McHugh Karen A, Anderson Scott C, Zhang Ling X, Teeple Erin, Waller Kimberly A, Elsaid Khaled A
Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Arthritis Rheum. 2010 Aug;62(8):2382-91. doi: 10.1002/art.27550.
To investigate whether cartilage degeneration is prevented or minimized following intraarticular injections of lubricin derived from human synoviocytes in culture, recombinant human PRG4 (rhPRG4), or human synovial fluid (SF) in a rat model of anterior cruciate ligament (ACL) injury.
Unilateral ACL transection (ACLT) was performed in Lewis rats (n = 45). Nine animals were left untreated. The remaining rats were given intraarticular injections (50 microl/injection) of either phosphate buffered saline (PBS) (n = 9), human synoviocyte lubricin (200 microg/ml; n = 9), rhPRG4 (200 microg/ml; n = 9), or human SF lubricin (200 microg/ml; n = 9) twice weekly beginning on day 7 after injury. Joints were harvested on day 32 after injury. Histologic analysis was performed using Safranin O-fast green staining, and articular cartilage degeneration was graded using the Osteoarthritis Research Society International (OARSI)-modified Mankin criteria. Histologic specimens were immunoprobed for lubricin and sulfated glycosaminoglycans. A 24-hour urine collection was performed on days 17 and 29 postinjury, and urinary C-terminal telopeptide of type II collagen (CTX-II) levels were measured.
Treatment with human synoviocyte lubricin resulted in significantly lower OARSI scores for cartilage degeneration compared with no treatment or PBS treatment (P < 0.05). Increased immunostaining for lubricin in the superficial zone chondrocytes and on the surface of cartilage was observed in lubricin-treated, but not untreated or PBS-treated, joints. On day 17, urinary CTX-II levels in human synoviocyte lubricin- and human SF lubricin-treated animals were significantly lower than those in untreated animals (P = 0.005 and P = 0.002, respectively) and in PBS-treated animals (P = 0.002 and P < 0.001, respectively).
After treatment with any of the 3 types of lubricin evaluated in this study, a reduction in cartilage damage following ACLT was evident, combined with a reduction in type II collagen degradation. Our findings indicate that intraarticular lubricin injection following an ACL injury may be beneficial in retarding the degeneration of cartilage and the development of posttraumatic OA.
在大鼠前交叉韧带(ACL)损伤模型中,研究关节内注射培养的人滑膜细胞来源的润滑素、重组人PRG4(rhPRG4)或人滑液(SF)后,软骨退变是否能得到预防或减轻。
对Lewis大鼠(n = 45)进行单侧ACL横断术(ACLT)。9只动物不做处理。其余大鼠在损伤后第7天开始每周两次关节内注射(每次50微升)磷酸盐缓冲盐水(PBS)(n = 9)、人滑膜细胞润滑素(200微克/毫升;n = 9)、rhPRG4(200微克/毫升;n = 9)或人SF润滑素(200微克/毫升;n = 9)。在损伤后第32天采集关节。采用番红O-固绿染色进行组织学分析,并用国际骨关节炎研究学会(OARSI)改良的曼金标准对关节软骨退变进行分级。对组织学标本进行润滑素和硫酸化糖胺聚糖的免疫检测。在损伤后第17天和第29天进行24小时尿液收集,并测量尿Ⅱ型胶原C端肽(CTX-II)水平。
与人滑膜细胞润滑素治疗相比,未治疗或PBS治疗的软骨退变OARSI评分显著更高(P < 0.05)。在接受润滑素治疗的关节中,观察到浅表区软骨细胞和软骨表面的润滑素免疫染色增加,而未治疗或PBS治疗的关节中未观察到。在第17天,接受人滑膜细胞润滑素和人SF润滑素治疗的动物尿CTX-II水平显著低于未治疗的动物(分别为P = 0.005和P = 0.002)以及接受PBS治疗的动物(分别为P = 0.002和P < 0.001)。
在本研究评估中的3种润滑素中的任何一种治疗后,ACLT后软骨损伤明显减轻,同时Ⅱ型胶原降解减少。我们的研究结果表明,ACL损伤后关节内注射润滑素可能有助于延缓软骨退变和创伤后骨关节炎的发展。